This study, called XANADO, is looking at how well standard neuromodulation therapies (SCS or DRG) work for people with chronic pain who also have diabetes or pre-diabetes. Neuromodulation uses devices to change nerve activity and reduce pain. Researchers want to see if information collected from your body, like physical and physiological data, can predict how well these therapies will work for you and if your treatment plan needs to be adjusted. The main goal is to measure changes in your pain scores at 3 and 6 months after starting the therapy. You can join if you are at least 18 years old and are scheduled for an Abbott neuromodulation system trial for at least 7 days. This study plans to enroll 30 participants, but its current recruitment status is unclear.

Study design

This is a single-center, non-randomized, open-label study, meaning you and your doctors will know what treatment you are receiving. It plans to include 30 participants.

What's involved

You would undergo assessments before, during, and after your trial with the SCS or DRG system. Your scheduled trial duration for the Abbott neuromodulation system must be at least 7 days.

Compensation

Not stated in the trial record.

Follow-up

Your pain scores will be measured at 3 months and 6 months after starting the therapy.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.